The main biguanides, metformin and phenformin, were introduced in 1957 as oral glucose-lowering agents to treat non-insulin- ...

... biguanides) plus sulfonylureas and risk of CVD and/or mortality, 2) adjusted relative risk (RR) or equivalent (i.e., hazard ... "biguanides;" and "metformin" and keyword "glimepiride." The search was restricted to include studies conducted only in human ...

Biguanide related lactic acidosis: incidence and risk factors. Arch Med Res 1992;23:19-24pmid:1308787. ... There is a significant divergence in opinion about whether metformin is associated with LA, mainly because a prior biguanide- ...

Phenformin, a biguanide, was associated with lactic acidosis and withdrawn from use (1) after causing increased mortality in ... Except for insulin, sulfonylureas and biguanides are the best studied and most widely used glucose-lowering agents. However, ... a newer biguanide, metformin, has risen to its current place as the leading oral therapy for diabetes based on its relative ...

A biguanide, phenformin, was approved in 1959 for use in the management of type 2 diabetes, but its association with fatal ... By 2001, the biguanide metformin (approved in 1995) had captured ∼33% of prescriptions, and the thiazolidinedione insulin ... More than a decade later in 1995, the second biguanide, metformin, was approved by FDA, followed in 1996 by glimepiride, a ... With the introduction of the biguanide metformin in 1995 and the thiazolidinedione insulin sensitizers in 1997, the proportion ...

... biguanides, insulin, glitinides, sulfonylureas, or thiazolidinediones); treatment for hypertension (ACE inhibitors, angiotensin ...

The biguanide metformin reduced the risk of diabetes by 31% in the DPP (32), the α-glucosidase inhibitor acarbose reduced the ... the biguanide metformin group or the placebo group. The latter interventions were combined with standard diet and exercise ...